Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report)’s stock is scheduled to reverse split on Monday, June 22nd. The 1-10 reverse split was announced on Wednesday, June 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, June 19th.
Lakewood-Amedex Biotherapeutics Stock Performance
NASDAQ:LABT opened at $0.57 on Thursday. Lakewood-Amedex Biotherapeutics has a one year low of $0.58 and a one year high of $9.82.
Analyst Ratings Changes
Separately, Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th.
About Lakewood-Amedex Biotherapeutics
We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.
See Also
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- 3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
- Why BitMine’s Selloff May Be Missing the Bigger Story
- 2 Quantum Stocks Are Drawing Capital as AI Infrastructure Hits a Wall
- After an Initial Panic, Wall Street’s Leaning Into Apple’s New Siri AI
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
